Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check3 days agoChange DetectedThe study page now displays a recruitment-closed notice and adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) to guide users.SummaryDifference0.1%

- Check10 days agoChange DetectedThe revision line at the bottom shows Revision: v3.5.5, replacing the previous v3.5.4.SummaryDifference0.0%

- Check17 days agoChange DetectedThe Ukraine location entry was updated to standardize the location as Kharkiv Oblast, Ukraine. The city line now reads Kharkiv, Kharkiv Oblast, Ukraine, 61039.SummaryDifference0.0%

- Check24 days agoChange DetectedThe page no longer displays the AbbVie sponsor attribution and the auxiliary sections 'Related Info' and 'Helpful Links Provided by', altering how users access sponsor details and related resources for this study.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page now displays a new revision tag, replacing the previous v3.5.3 with v3.5.4. This indicates a software release or UI/template update to the page rather than changes to the study details or content.SummaryDifference0.0%

- Check39 days agoChange DetectedTwo trial-site entries were updated to use correctly spelled city names with diacritics (Malmö and Taoyuan City) instead of the previously listed forms. The update standardizes geographic identifiers on the study's site list while preserving the country and postal code information.SummaryDifference0.0%

Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.